EC Number |
Inhibitors |
Structure |
---|
1.6.5.5 | 2,3-Dimercaptopropanol |
- |
|
1.6.5.5 | 2,5-Dichloro-3,6-dihydroxy-1,4-benzoquinone |
i.e. chloranilic acid, noncompetitive with respect to both NADPH and 9,10-phenanthrenequinone |
|
1.6.5.5 | 4-chloromercuribenzoate |
both NADPH and NADP1 suppress the inhibition, but NADH does not |
|
1.6.5.5 | 4-Hydroxycoumarin |
reversible time-independent inhibition. Only dicoumarol, 4-hydroxycoumarin and warfarin inhibit in micromolar ranges. 7-Hydroxy-4-methylcoumarin is ineffective. Competitive inhibition with respect to 2,6-dichlorophenolindophenol, uncompetitive with respect to NADPH. Phenolic hydroxyl group at the C-4 position in the coumarin skeleton is important for the maximal inhibition. Sequence of potency for the inhibitors in descending order: dicoumarol, 4-hydroxycoumarin, warfarin, coumarin |
|
1.6.5.5 | 5,5'-dithiobis(2-nitrobenzoate) |
- |
|
1.6.5.5 | 5,5'-dithiobis(2-nitrobenzoate) |
inactivation is caused by a modification of one Cys per subunit, reactivation by dithiothreitol or KCN. NADPH partially protects from inactivation, 9,10-phenanthrenequinone enhances the modification |
|
1.6.5.5 | ADP |
10% inhibition at 0.2 mM |
|
1.6.5.5 | Cibacron blue 3GA |
- |
|
1.6.5.5 | Cibacron blue 3GA |
inhibits the reaction with NADPH and 9,10-phenanthrenequinone. Linear mixed type inhibition with respect to NADPH and noncompetitive with respect to 9,10-phenanthrenequinone |
|
1.6.5.5 | Colchicine |
noncompetitive with respect to 9,10-phenanthrenequinone and 1,2-naphthoquinone, uncompetitive with respect to NADPH. Binding of colchicine occurs at or close to the NADPH binding site |
|